Mortality within the longest · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids showed no clear difference in all‐cause mortality (during the index hospital admission, or within… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
Pulmonary complications (as defined by study authors, including pneumonia, embolism, reduced pulmonary function, prolonged ventilation, and pleural effusion, during the index hospital admission) · adults diagnosed with coronary artery disease or cardiac valve disease, and candidates for cardiac surgery with cardiopulmonary bypass
Prophylactic corticosteroids may leads to lower pulmonary complications (as defined by study authors, including… compared with placebo or no corticosteroids (low certainty).
1 finding from 1 review
New initiation of renal replacement therapy – at longest available · people with AHF
Ultrafiltration (UF) showed no clear difference in new initiation of renal replacement therapy – at longest available compared with usual care (UC) (low certainty).
1 finding from 1 review
Cardiovascular mortality · health problem or population
Summary of findings table ‐ Psychological treatment showed no clear difference in cardiovascular mortality ‐ long‐term compared with control; GRADE not reported.
1 finding from 1 review
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with low cardiac output syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality: 60 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality: range 4 to 12 months · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause long‐term mortality: range 4 to 12 months compared with dobutamine (low certainty).
1 finding from 1 review
All‐cause long‐term mortality: range 4 to 6 months · adults with cardiogenic shock or low cardiac output syndrome
It is very uncertain whether levosimendan changes all‐cause long‐term mortality: range 4 to 6 months compared with placebo (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause long‐term mortality · adults with cardiogenic shock
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Cardiovascular mortality · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term cardiovascular mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Myocardial infarction · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term myocardial infarction (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Overall adverse events (pooled short and long term) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes overall adverse events (pooled short and long term) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Long‐term revascularisation (≥ 1 year after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term revascularisation (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality (all cause) Long‐term · people with chronic ischaemic heart disease and congestive heart failure
The intervention may leads to lower mortality (all cause) Long‐term (low certainty).
1 finding from 1 review